| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, Bethesda, Maryland 20892 [Z. S., L. D., R. L., N. E. L., P. N. N., P. M. B.], and Cancer Research Institute and Department of Chemistry, Arizona State University, Tempe, Arizona 85287 [M. D. W., G. R. P.]
Bryostatin 1 is a potential cancer chemotherapeutic agent in Phase II clinical trials, with positive responses observed for malignant melanoma, among other tumors. The bryostatins are known to be potent ligands for protein kinase C (PKC), functioning as partial antagonists. In the present study, we explore the mechanism by which the bryostatins inhibit growth of B16/F10 mouse melanoma cells in vitro. Three experimental approaches suggest that the growth inhibition is independent of PKC. First, we characterized in detail the translocation and down-regulation of the PKC isozymes 
, 
, and 
in response to phorbol ester and bryostatin 1 in these cells. Although the dose-response curves obtained for the translocation-activation of PKC isozymes showed good correlation with the growthenhancing activity of phorbol 12-myristate 13-acetate, for no PKC isozyme was there a good correlation with the growth-inhibitory activity of bryostatin 1. Second, inhibition of PKC enzymatic activity by the specific PKC inhibitor bisindolyl-maleimide I did not block the inhibition of thymidine incorporation induced by bryostatin 1. Finally, 26-epi-bryostatin 1, a stereoisomer of the naturally occurring bryostatin 1 designed to have markedly reduced affinity for PKC, inhibited the growth of the B16/F10 melanoma cell lines with potency similar to that of bryostatin 1. We confirmed here that 26-epi-bryostatin 1 showed 60-fold reduced affinity for PKC and 30-60-fold reduced potency to translocate and downregulate PKC isozymes compared with bryostatin 1. We presume that the principal toxicity of bryostatin 1 reflects its interaction with PKC, and we would thus predict that epi-bryostatin 1 would be less toxic. Indeed, we found at least 10-fold reduced toxicity of 26-epi-bryostatin 1 in C57BL/6 mice compared with bryostatin 1. We conclude that the growth inhibition of the bryostatins, at least in this system, does not result from interaction with PKC. As exemplified by 26-epi-bryostatin 1, this insight permits the design of analogues with comparable growth inhibition to bryostatin 1 but with reduced toxicity.
1 To whom requests for reprints should be addressed, at Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, Building 37, Room 3A01, 37 Convent Drive, MSC 4255, Bethesda, MD 20892-4255. Phone: (301) 496-3189; Fax: (301) 496-8709.
Received 2/ 5/96. Accepted 3/ 4/96.
This article has been cited by other articles:
|
|
 |
|
  H. Li, W. Wojciechowski, C. Dell'Agnola, N. E. Lopez, and I. Espinoza-Delgado IFN-{gamma} and T-bet Expression in Human Dendritic Cells from Normal Donors and Cancer Patients Is Controlled through Mechanisms Involving ERK-1/2-Dependent and IL-12-Independent Pathways J. Immunol., September 15, 2006; 177(6): 3554 - 3563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Choi, T. Hyman, and P. M. Blumberg Differential Effect of Bryostatin 1 and Phorbol 12-Myristate 13-Acetate on HOP-92 Cell Proliferation Is Mediated by Down-regulation of Protein Kinase C{delta}. Cancer Res., July 15, 2006; 66(14): 7261 - 7269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Tuthill, C. E. Oki, and P. S. Lorenzo Differential effects of bryostatin 1 and 12-O-tetradecanoylphorbol-13-acetate on the regulation and activation of RasGRP1 in mouse epidermal keratinocytes. Mol. Cancer Ther., March 1, 2006; 5(3): 602 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms J. Immunol., June 15, 2005; 174(12): 7859 - 7868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Do, V. L. Hegde, P. S. Nagarkatti, and M. Nagarkatti Bryostatin-1 Enhances the Maturation and Antigen-Presenting Ability of Murine and Human Dendritic Cells Cancer Res., September 15, 2004; 64(18): 6756 - 6765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Curiel, C. S. Garcia, L. Farooq, M. F. Aguero, and I. Espinoza-Delgado Bryostatin-1 and IL-2 Synergize to Induce IFN-{gamma} Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy J. Immunol., November 1, 2001; 167(9): 4828 - 4837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Gschwend, W. R. Fair, and C. T. Powell Bryostatin 1 Induces Prolonged Activation of Extracellular Regulated Protein Kinases in and Apoptosis of LNCaP Human Prostate Cancer Cells Overexpressing Protein Kinase Calpha Mol. Pharmacol., June 1, 2000; 57(6): 1224 - 1234. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. A. Koutcher, M. Motwani, K. L. Zakian, X.-K. Li, C. Matei, J. P. Dyke, D. Ballon, H. H. Yoo, and G. K. Schwartz The in Vivo Effect of Bryostatin-1 on Paclitaxel-induced Tumor Growth, Mitotic Entry, and Blood Flow Clin. Cancer Res., April 1, 2000; 6(4): 1498 - 1507. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. van Gijn, X. Zuidema, A. Bult, and J. H. Beijnen Protein kinase C as a target for new anti-cancer agents Journal of Oncology Pharmacy Practice, December 1, 1999; 5(4): 166 - 178. [Abstract] [PDF]
|
|
|
|
|
|
P. S. Lorenzo, K. Bogi, K. M. Hughes, M. Beheshti, D. Bhattacharyya, S. H. Garfield, G. R. Pettit, and P. M. Blumberg Differential Roles of the Tandem C1 Domains of Protein Kinase C {{delta}} in the Biphasic Down-Regulation Induced by Bryostatin 1 Cancer Res., December 1, 1999; 59(24): 6137 - 6144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Brodie, K. Bogi, P. Acs, P. S. Lorenzo, L. Baskin, and P. M. Blumberg Protein Kinase C delta (PKCdelta ) Inhibits the Expression of Glutamine Synthetase in Glial Cells via the PKCdelta Regulatory Domain and Its Tyrosine Phosphorylation J. Biol. Chem., November 13, 1998; 273(46): 30713 - 30718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Wender, J. DeBrabander, P. G. Harran, J.-M. Jimenez, M. F. T. Koehler, B. Lippa, C.-M. Park, C. Siedenbiedel, and G. R. Pettit The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1 PNAS, June 9, 1998; 95(12): 6624 - 6629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Lorenzo, K. Bogi, P. Acs, G. R. Pettit, and P. M. Blumberg The Catalytic Domain of Protein Kinase Cdelta Confers Protection from Down-regulation Induced by Bryostatin 1 J. Biol. Chem., December 26, 1997; 272(52): 33338 - 33343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Matthews, G. R. Pettit, and E. Rozengurt Bryostatin 1 Induces Biphasic Activation of Protein Kinase D in Intact Cells J. Biol. Chem., August 8, 1997; 272(32): 20245 - 20250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Bosco, S. Rottschafer, L. S. Taylor, J. R. Ortaldo, D. L. Longo, and I. Espinoza-Delgado The Antineoplastic Agent Bryostatin-1 Induces Proinflammatory Cytokine Production in Human Monocytes: Synergy With Interleukin-2 and Modulation of Interleukin-2Rgamma Chain Expression Blood, May 1, 1997; 89(9): 3402 - 3411. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
